Adverse Event reporting information can be found in footer

Request a Meeting

Consistent colon coverage for your patients 1-5

Click on one of the links below

SUMMARY

PENTASA®, the 5-ASA of choice for your mild to moderate UC patients1-7

 

PENTASA® is the unique time-dependent formulation which releases 5-ASA regardless of pH1-5

 

  • ensuring consistent proximal to distal colon coverage
  •  

  • removing the uncertainty of fluctuating intestinal pH levels

 

Optimised PENTASA® Treatment:

 

  • achieves remission within 2 weeks and maintains remission for 12 months8,9*
  •  

  • has proven efficacy in moderate and left-sided UC patients8,10,11*
  •  

  • achieves and maintains high rates of mucosal healing8,11*
  •  

  • offers once daily formulations and high adherence3-5,12

* Included OD PENTASA® enema for the first 4 weeks

THE ONLY TIME DEPENDENT 5-ASA 1-5,13-27

Optimising mesalazine delivery to the whole colon is important in treating patients with mild to moderate UC

All other 5-ASAs

pH-dependent formulations release 5-ASA where the pH is >6 but can differ in extent of delivery 13-27

 

For example, Salofalk®’s absorption is highest in proximal gut regions and lowest in distal gut areas 13-19

 

pH as low as <2.3 has been reported in the colon, suggesting that pH-dependent formulations may not be able to disperse in some patients 10,28

PENTASA®

The only time-dependent formulation which releases 5-ASA regardless of intestinal pH 1-5,13-27

 

Time-dependent release ensures consistent delivery throughout the entire colon 1-5

 

80% delivered to the large colon, ensuring efficacy in UC, including left-sided disease 29

 

ALWAYS SIMPLE ONCE-DAILY FORMULATIONS 1-7

The only 5-ASA sachet licensed to be taken with yoghurt 3-5,16-19

PENTASA® sachets can also be taken with water, orange juice, and with or without food. 3-5

LEFT-SIDED DISEASE

80% of patients with UC have left sided disease 30, and with PENTASA®’s time-dependent release you can achieve consistent delivery of mesalazine throughout the entire colon, ensuring efficacy in LSD. 29

Achieving remission* in 8 weeks 11

4g daily for 8 weeks

1g OD for 4 weeks

Compared to 52.1% of patients in the overall population

Maintaining remission* to 12 Months 10

2g OD for 12 months

Compared to 71% of patients in the overall population

* Remission: Patients (%) achieving UC-DAI ≤ 1 , Images of medication not shown to scale

MUCOSAL HEALING

British Society of Gastroenterology (BSG) consensus guidelines on managing IBD in adults states that symptomatic remission, with mucosal healing, should be the target of medical therapy in UC 31. Mucosal healing is an important treatment goal and has been correlated with long-term disease remission rates, reduced risk of colorectal cancer, and improved patient quality of life. 11,31

Mucosal Healing Scores* at 8 weeks 11

4g daily for 8 weeks

1g OD for 4 weeks

Compared to 71% on twice-daily (BD) dosing (p=0.007)

Mucosal Healing Scores* after 12 months 8

2g OD for 12 months

Compared to 81% of patients on BD dosing (p=not significant)

* Mucosal Healing: UC-DAI endoscopic sub-score of ≤ 1, Images of medication not shown to scale

SPEED OF ACTION - EFFECTIVE IN 2 WEEKS 9

Faster symptom resolution in mild to moderate UC with mesalazine can improve quality of life, and increase treatment adherence. 9

Achieving improvement* in 2 weeks 9

4g daily for 8 weeks

1g OD for 4 weeks

Achieving remission* in 2 weeks 9

4g daily for 8 weeks

1g OD for 4 weeks

* Improvement: Patients (%) achieving a decrease in abbreviated UC-DAI of ≥ 2 from baseline
* Remission: Patients (%) achieving abbreviated UC-DAI < 2

PATIENT EXPERIENCE

In this video you will hear Amy’s UC journey from initial diagnosis to eventual treatment with PENTASA® sachets

RESOURCES

Visit our Resource Centre to see the range of support materials available for your patients

References

Job Code: UK-PA-2500023 Date of Preparation: June 2025

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.